SELLAS Life Sciences Gr analyst ratings
SELLAS Life Sciences Gr analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/28/2022 | 158.62% | Cantor Fitzgerald | $10 → $6 | Maintains | Overweight |
| 07/21/2021 | 675.86% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 11/15/2019 | 417.24% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 04/08/2019 | 93.97% | Alliance Global Partners | → $4.5 | Initiates Coverage On | → Buy |
| 11/01/2018 | 460.34% | Oppenheimer | → $13 | Initiates Coverage On | → Outperform |
| 07/20/2018 | 115.52% | Maxim Group | $13 → $5 | Maintains | Buy |
| 04/02/2018 | 374.14% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/19/2018 | — | Maxim Group | Upgrades | Hold → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 06/28/2022 | 158.62% | 坎託·菲茨傑拉德 | 10 美元 → 6 美元 | 維護 | 超重 |
| 07/21/2021 | 675.86% | 坎託·菲茨傑拉德 | → 18 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 11/15/2019 | 417.24% | Maxim 集團 | → 12 美元 | 升級 | 持有 → 買入 |
| 2019 年 8 月 4 日 | 93.97% | 聯盟全球合作伙伴 | → 4.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2018 年 1 月 11 日 | 460.34% | 奧本海默 | → 13 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 07/20/2018 | 115.52% | Maxim 集團 | 13 美元 → 5 美元 | 維護 | 買 |
| 2018 年 2 月 4 日 | 374.14% | HC Wainwright & Co. | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2018 年 3 月 19 日 | — | Maxim 集團 | 升級 | 持有 → 買入 |
SELLAS Life Sciences Gr Questions & Answers
SELLAS 生命科學 Gr 問題與解答
The latest price target for SELLAS Life Sciences Gr (NASDAQ: SLS) was reported by Cantor Fitzgerald on June 28, 2022. The analyst firm set a price target for $6.00 expecting SLS to rise to within 12 months (a possible 158.62% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2022年6月28日公佈了SELLAS Life Sciences Gr（納斯達克股票代碼：SLS）的最新目標股價。該分析公司將目標股價定爲6.00美元，預計SLS將在12個月內升至12個月內（可能上漲158.62％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for SELLAS Life Sciences Gr (NASDAQ: SLS) was provided by Cantor Fitzgerald, and SELLAS Life Sciences Gr maintained their overweight rating.
SELLAS Life Sciences Gr（納斯達克股票代碼：SLS）的最新分析師評級由坎託·菲茨傑拉德提供，SELLAS Life Sciences Gr維持增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SELLAS Life Sciences Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SELLAS Life Sciences Gr was filed on June 28, 2022 so you should expect the next rating to be made available sometime around June 28, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與SELLAS Life Sciences Gr的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。SELLAS Life Sciences Gr的最新評級是在2022年6月28日公佈的，因此您應該預計下一個評級將在2023年6月28日左右公佈。
While ratings are subjective and will change, the latest SELLAS Life Sciences Gr (SLS) rating was a maintained with a price target of $10.00 to $6.00. The current price SELLAS Life Sciences Gr (SLS) is trading at is $2.32, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的SELLAS生命科學集團（SLS）評級維持不變，目標股價爲10.00美元至6.00美元。SELLAS Life Sciences Gr（SLS）的當前交易價格爲2.32美元，超出了分析師的預期區間。